Novel Protein Characterization for Biopharma Development

Protein stability is one of the most important critical quality attributes for a new biological drug. Unstable or misfolded proteins are prone to aggregation and precipitation, which can lead to lower activity as well as increased immunogenicity. There has been a long-standing interest in renaturing unfolded, misfolded or precipitated proteins. In this webinar, our expert speakers will demonstrate how thermal and pressure stress changed the structure and melting point of two model proteins and resulted in the discovery of different structural rearrangements. They will then discuss a novel method for solubilizing and refolding proteins using hydrostatic pressure to generate proteins whose structure matches that of the native protein, as confirmed by microfluidic modulation spectroscopy. Dr. Alexander Lazarev Chief Scientific Officer Pressure BioSciences alazarev@pressurebiosciences.com When providing a biography, remember this is used in the webinar promotion so be sure to include as much details as possible and mention their professional accomplishments/accolades. This may be shortened to include their key achievements for their introduction. Dr. Alexander Lazarev, Ph.D. joined Pressure BioSciences in April 2006 as Director of Research and Development and was promoted to Vice President of Research and Development in March 2007. Dr. Lazarev was promoted to Chief Science Officer in December 2018. Prior to joining Pressure BioSciences, Dr. Lazarev worked as a Visiting Scientist at the Barnett Institute of Chemical and Biological Analysis at Northeastern University and served as a Director of New Technology Development at Proteome Systems, Inc., where he was involved in research and development of innovative proteomic analysis applications. Dr. Lazarev previously held senior research positions at Genomic Solutions, Inc. and PhytoChem Technologies, Inc. Most of Dr. Lazarev’s scientific career has been dedicated to the development of methods and applications for biochemical analysis. Dr. Lazarev has been elected as an Executive Board member of MASSEP.org, a non-profit scientific discussion forum dedicated to the promotion and improvement of chromatography and other analytical technologies. Dr. Lazarev earned his undergraduate and graduate degrees at the University of Kazan, Russian Federation. Dr. Vera Gross Director of Applications Development Pressure BioSciences When providing a biography, remember this is used in the webinar promotion so be sure to include as much details as possible and mention their professional accomplishments/accolades. This may be shortened to include their key achievements for their introduction. Vera Gross, Ph.D. is the Director of Applications Development at Pressure BioSciences, Inc. Vera started at PBI in the early days of the 21st century (2007 to be exact) as an R&D scientist using her experience in cell and molecular biology to develop high-pressure applications for cell lysis and extraction of various biomolecules. For the past several years Vera has focused on using PBI’s Barofold Technology to examine and optimize high pressure-based approaches for modulating protein folding with an emphasis on generating soluble, active, and stable proteins from purified inclusion bodies and other protein aggregates. Dr. Valerie Collins, PhD Applications Manager RedShiftBio When providing a biography, remember this is used in the webinar promotion so be sure to include as much details as possible and mention their professional accomplishments/accolades. This may be shortened to include their key achievements for their introduction. Valerie joined RedShiftBio in 2018 and her experience with Microfluidic Modulation Spectroscopy began prior to that, as the first external beta tester of the company’s original AQS3pro system. Valerie possesses a wealth of biophysical characterization experience and a research background in structural and spectroscopic characterization of proteins and peptides, focusing on amyloidosis. Valerie leads RedShiftBio’s internal and external field applications team and oversees all proof-of-concept studies worldwide.